Figures computed from official regulatory filings — .
Analysttarget 24.33 USD (+171%) · consensus 4.86/5 · 7 buy · 0 hold · 0 sell
Ownershipinsiders 2.51% · institutions 96.02% · short 11.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Benitec Biopharma Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
38 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BUCHI J KEVINtrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Friedman David Matthew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mates Sharon | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cowen Aarontrack record | Buy | $95.1K | conv 42Cluster | SEC |
| Cowen Aarontrack record | Buy | $187.6K | conv 37Cluster | SEC |
| Cowen Aarontrack record | Buy | $547.4K | conv 42Cluster | SEC |
| Cowen Aarontrack record | Buy | $884.4K | conv 37Cluster | SEC |
| Cowen Aarontrack record | Buy | $33K | conv 37Cluster | SEC |
| Cowen Aarontrack record | Buy | $155.7K | conv 37Cluster | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $17K | conv 45First in 12mo | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $34.9K | conv 27 | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $27.9K | conv 37 | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $160.1K | conv 37 | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $201.1K | conv 42 | SEC |
| Averill Madison Master Fund, Ltd.track record | Buy | $97.8K | conv 45First in 12mo | SEC |
| Mates Sharon | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Francis Peter | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mehta Kishan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BUCHI J KEVINtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith Edward F | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boston Megan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mukadam Sophie | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Banks Jerel A. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SUVRETTA CAPITAL MANAGEMENT, LLCtrack record | Buy | $9.9M | conv 53Unusual size | SEC |
| SUVRETTA CAPITAL MANAGEMENT, LLCtrack record | Buy | $10.1M | conv 68Unusual size | SEC |